Syringe Infusion Systems – An Electrically Powered Precise Smart Medication to Boost Drug Delivery Infusion Systems Market

Drug Delivery Infusion pump is a medical device, used to deliver fluids into a patient’s body in a controlled manner. Infusion pumps can deliver fluids in large or small amounts, and can also be used to deliver nutrients or medications, such as insulin or hormone-related, antibiotics, chemotherapy drugs, and pain relievers. Despite its relative invasiveness and technological maturity, instrument-based infusion and injection of pharmaceutical preparations commonly is regarded as the most accurate, effective, reliable, and reproducible method of therapeutic drug and fluid delivery. A variety of drug infusion/injection techniques are used at hospitals and alternate care sites for the management of patients with acute and chronic medical conditions warranting or responsive to pharmacologic therapy.

Major clinical applications of drug and fluid infusion and injection tools include anesthesia delivery, antibiotic/antiviral therapy, bone marrow, and organ transplant support therapy, cardiovascular disease management, chemotherapy, diabetes management, hydration therapy, nutritional support, pain management, and transfusion therapy. Systemic or local injection/infusion of medical preparations is an invasive form of drug therapy used in cases in which other delivery routes are considered inadequate, ineffective, or unfeasible due to pharmacologic incompatibility or patient intolerance and noncompliance.

The global drug delivery infusion systems market is segmented based on product type, which includes volumetric pumps, syringe infusion systems, ambulatory infusion systems, implantable infusion systems, insulin infusion pumps, enteral infusion systems, and others. By application segment, the drug delivery infusion systems market is segmented into oncology/chemotherapy, diabetes, analgesia, nutrition, pediatrics, and others; by end-user includes hospitals, ambulatory surgical centers, home care settings, and others

Syringe Infusion Systems is the leading product type segment for the drug delivery infusion systems market, holding a major share in 2017. The segment is exhibiting significant growth owing to increased product launches in recent years, followed by precise drug delivery. Syringe infusion systems are preferred for lower flow rates and low-volume infusions. The volume delivered can go up to 100 ml of fluid at flow rates of 0.1-100 ml/hour.

For instance, in January 2018, vTitan Corporation introduced the world’s first of its kind closed-loop infusion pumps, Accuflow SP-550 and Accuflow IBP-550 Syringe Infusion Pumps. Both pumps are for critical care medication administration.

On  April 10, 2017, Repro Med Systems, Inc. have received approval for FREEDOM60 Infusion System in Germany for reimbursement. The RMS FREEDOM60 system provides durable and reliable syringe driver and high-quality HIgH-Flo subcutaneous safety needle sets for immunoglobulin, antibiotics and many other therapies

In August 2016, Smiths Medical, one a leading global medical device manufacturer, introduced its Medfusion 4000 wireless syringe infusion pumps. The Medfusion 4000 wireless syringe pump provides safe, accurate medication delivery to patients in the pediatric and neonatal intensive care units, adult critical care unit and the operating room.

The global drug delivery infusion systems market was valued at US$ 10,085.5 billion in 2017 and is expected to witness a CAGR of 5.5% over the forecast period (2019–2026).

Growing prevalence of chronic diseases and high use of chemotherapy by Infusion System:

Chronic prevalence is one of the major factors for the high usage of drug delivery infusion systems. Chronic diseases are responsible for 60% of all deaths worldwide. In Americans at least six in ten live with one of chronic diseases, related to heart, cancer, stroke, or diabetes.

In 2017, 30.3 million US adults had diabetes. Diabetes is the seventh leading cause of death in the US. Around 630,000 Americans die from heart disease each year. Coronary heart disease is the most common type of heart disease, killed about 366,000 people in 2015.

Chemotherapy now days is highly depending on infusion systems for drug delivery. The therapy involves the infusion of cytotoxic anti-neoplastic drugs and other medications directly into the bloodstream to inhibit the growth and spreading of cancer cells. Infusion systems provide short-term access to the bloodstream. Physicians use these systems to deliver chemotherapeutic agents to individuals receiving chemotherapy once every few weeks.

Integrated or closed catheters offer fully (360 degrees) encased needle tip protection and have a passive design to minimize needlestick injuries. These infusion systems have a closed system for managing the circulation of blood. They also provide safety benefits, such as a reduction in medical errors and enhanced efficacy, for individuals undergoing chemotherapy.

Infusion systems and complications:

The complications associated with infusion systems might hamper the market potential.

Infusion systems involve the risk of infiltration and extravasation for both patients and caretakers, which is a concern that limits the adoption. The use of peripheral intravenous catheters can cause phlebitis or acute inflammation of the internal lining of veins at catheter insertion sites.  Infusion systems can cause occlusions, which can restrict the administration of fluids. Thrombotic occlusions are blood clots that develop around the tip of catheters. Movement of intravenous catheters post insertion can cause trauma to the walls of veins, leading to non-thrombotic or thrombotic occlusions.

The infusion system product recall is also one of the major market restraints.

For instance, Medtronic announced a voluntary recall of diabetes infusion sets on September 10, 2017. Medtronic determined through a recent report from various healthcare professionals, patients and through a root cause analysis shows that the infusion sets may be susceptible to being blocked by fluid during the process of priming/fill-tubing. This situation can lead to potential over-delivery of insulin shortly after an infusion set change, which may cause hypoglycemia.

Product launches and approvals:

The product launches and approvals are the dominant strategies adopted by the market players to enhance their product portfolio in the drug delivery infusion systems market.

For instance, in October 2018, Medtronic Plc received the FDA approved for its new SynchroMed II myPTM Personal Therapy Manager for patients with chronic pain. The company explains that the device ‘enables patients to alleviate their unpredictable pain by delivering on-demand boluses, or drug doses, within therapeutic limits set by their physician.’

In August, 2018, Baxter received CE Mark and regulatory approval for New Evo IQ Infusion System in the United Kingdom, Ireland, Australia, and New Zealand

Several such key product launches and approvals hits the market players with high market share margin. Other prominent key manufacturers for drug delivery infusion systems market are Acromed AG., B. Braun Melsungen AG, Becton Dickinson and Company, Flowonix Medical Inc, Fresenius Kabi, Iradimed Corporation, Terumo Corporation, ICU Medical, Inc, and other.